The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study

BMC Nephrology

David W Johnson⁷  Philip Clayton⁸  Kym M Bannister⁵  Kathryn J Wiggins²  Neil Boudville M⁴  Fiona G Brown¹  Stephen P McDonald⁶  Carmel M Hawley³  Sunil V Badve³  Yeoungjee Cho³ 

[1]Department of Nephrology, Monash Medical Center, Melbourne, Australia

[2]Department of Renal Medicine,, Royal Melbourne Hospital,, Melbourne, Australia

[3]Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia

[4]School of Medicine and Pharmacology, University of Western Australia, Perth, Australia

[5]Department of Nephrology, Royal Adelaide Hospital, Adelaide, Australia

[6]Department of Nephrology & Transplantation Services, University of Adelaide at the Queen Elizabeth Hospital, Adelaide, Australia

[7]Department of Nephrology, Level 2, ARTS Building, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Qld, 4102, AUSTRALIA

[8]Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia

关键词: Remoteness;    Relapse;    Outcomes;    Peritonitis;    Peritoneal Dialysis;    Microbiology;    Fungus;    Bacteria;    Antibiotics;   

Others  :  1083172
DOI  :  10.1186/1471-2369-13-41

 received in 2012-01-27, accepted in 2012-06-15,  发布年份 2012

【 摘 要 】

Background

The aim of the study was to determine whether distance between residence and peritoneal dialysis (PD) unit influenced peritonitis occurrence, microbiology, treatment and outcomes.

Methods

The study included all patients receiving PD between 1/10/2003 and 31/12/2008, using ANZDATA Registry data.

Results

365 (6%) patients lived ≥100 km from their nearest PD unit (distant group), while 6183 (94%) lived <100 km (local group). Median time to first peritonitis in distant patients (1.34 years, 95% CI 1.07-1.61) was significantly shorter than in local patients (1.68 years, 95% CI 1.59-1.77, p = 0.001), whilst overall peritonitis rates were higher in distant patients (incidence rate ratio 1.32, 95% CI 1.20-1.46). Living ≥100 km away from a PD unit was independently associated with a higher risk of S. aureus peritonitis (adjusted odds ratio [OR] 1.64, 95% CI 1.09-2.47). Distant patients with first peritonitis episodes were less likely to be hospitalised (64% vs 73%, p = 0.008) and receive antifungal prophylaxis (4% vs 10%, p = 0.01), but more likely to receive vancomycin-based antibiotic regimens (52% vs 42%, p < 0.001). Using multivariable logistic regression analysis of peritonitis outcomes, distant patients were more likely to be cured with antibiotics alone (OR 1.55, 95% CI 1.03-2.24). All other outcomes were comparable between the two groups.

Conclusions

Living ≥100 km away from a PD unit was associated with increased risk of S. aureus peritonitis, modified approaches to peritonitis treatment and peritonitis outcomes that were comparable to, or better than patients living closer to a PD unit. Staphylococcal decolonisation should receive particular consideration in remote living patients.

【 授权许可】

   
2012 Cho et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Johnson DW, Chang S, Excell L, Livingston B, Bannister K, McDonald SP: Peritoneal Dialysis. In ANZDATA Registry Report 2006. Edited by McDonald SP, Excell L. Australian and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia; 2007:87-103.
• [2]Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown F, Bannister K, Wiggins KJ: Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis 2009, 53:290-297.
• [3]Barraclough K, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister K, Johnson DW: Polymicrobial Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes. Am J Kidney Dis 2010, 55:121-131.
• [4]Barraclough K, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister KM, Johnson DW: Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases. Nephrol Dial Transplant 2009, 24:3834-3839.
• [5]Edey M, Hawley C, McDonald SP, Brown F, Rosman JB, Wiggins KJ, Bannister K, Johnson DW: Enterococcal peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment and Outcomes in 116 cases. Nephrol Dial Transplant 2009, 25:1272-1278.
• [6]Fahim M, Hawley CM, McDonald SP, Brown F, Rosman JB, Wiggins KJ, Bannister K, Johnson DW: Culture-Negative Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment and Outcomes in 435 cases. Am J Kidney Dis 2009, 55:690-697.
• [7]Fahim M, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister KM, Johnson DW: Coagulase negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases. Nephrol Dial Transplant 2010, 25:3386-3392.
• [8]Govindarajulu S, Hawley C, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister K, Johnson DW: Staphylococcus aureus Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment and Outcomes in 503 cases. Perit Dial Int 2009, 30:311-319.
• [9]Jarvis E, Hawley C, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister KM, Johnson DW: Non-pseudomonas gram negative peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 837 cases. Kidney Int 2010, 78:408-414.
• [10]Jose M, Johnson DW, Mudge DW, Tranaeus A, Voss D, Walker R, Bannister KM: Peritoneal dialysis practice in Australia and New Zealand: A call to action. Nephrology 2011, 16:19-29.
• [11]Miles R, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister K, Johnson DW: Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int 2009, 76:622-628.
• [12]O'Shea S, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister KM, Johnson DW: Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. BMC Nephrol 2009, 10:19. BioMed Central Full Text
• [13]Siva B, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister KM, Johnson DW: Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases. Clin J Am Soc Nephrol 2009, 4:957-964.
• [14]Lim WH, Boudville N, McDonald SP, Gorham G, Johnson DW, Jose M: Remote indigenous peritoneal dialysis patients have higher risk of peritonitis, technique failure, all-cause and peritonitis-related mortality. Nephrol Dial Transplant 2011, 26:3366-3372.
• [15]Tonelli M, Hemmelgarn B, Culleton B, Klarenbach S, Gill JS, Wiebe N, Manns B: Mortality of Canadians treated by peritoneal dialysis in remote locations. Kidney Int 2007, 72:1023-1028.
• [16]Lim WH, Johnson DW, McDonald SP: Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: analysis of ANZDATA. Nephrology (Carlton) 2005, 10:192-197.
• [17]Pignatari A, Pfaller M, Hollis R, Sesso R, Leme I, Herwaldt L: Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol 1990, 28:1898-1902.
• [18]Xu G, Tu W, Xu C: Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2010, 25:587-592.
• [19]Badve SV, Hawley CM, Johnson DW: Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients. Nephrol Dial Transplant Plus 2009, 2:508.
• [20]Jose M, Johnson DW, Mudge DW, Tranaeus A, Voss D, Walker R, Bannister KM: Peritoneal dialysis practice in Australia and New Zealand: A call to action. Nephrology 2011, 16:19-29.
• [21]Sood MM, Komenda P, Sood AR, Reslerova M, Verrelli M, Sathianathan C, Eng L, Eng A, Rigatto C: Adverse outcomes among Aboriginal patients receiving peritoneal dialysis. CMAJ 2010, 182:1433-1439.
• [22]Martin LC, Caramori JC, Fernandes N, Divino-Filho JC, Pecoits-Filho R, Barretti P: Geographic and Educational Factors and Risk of the First Peritonitis Episode in Brazilian Peritoneal Dialysis Study (BRAZPD) Patients. Clin J Am Soc Nephrol 2011, 6:1944-1951.
• [23]Davenport A: Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002–2003. Perit Dial Int 2009, 29:297-302.
• [24]Kavanagh D, Prescott GJ, Mactier RA: Peritoneal dialysis-associated peritonitis in Scotland (1999–2002). Nephrol Dial Transplant 2004, 19:2584-2591.
• [25]Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson DW, Kuijper EJ, Lye WC, Salzer W: Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010, 30:393-423.
• [26]Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, Price V, Ramalakshmi S, Szeto CC: ISPD - position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 2011, 31:614-630.